omaolo.fi Vaccinations
25.02.2021

Appoint­ment book­ing for coro­n­avirus vac­ci­na­tion for per­sons who belong to risk group 1 opens

Appoint­ment book­ing for coro­n­avirus vac­ci­na­tions for 18–69-year-olds who live in Soite’s area and belong to risk group 1 opens in the elec­tron­ic Oma­hoito ser­vice on Fri­day 26th of Feb­ru­ary 2021 at 12 noon and on Soite’s phone line for appoint­ment book­ing on Tues­day 2nd of March 2021. Per­sons who belong to risk groups will no longer be per­son­al­ly con­tact­ed about coro­n­avirus vac­ci­na­tions: instead, every­one has to book an appoint­ment themselves.

You can book an appoint­ment for a coro­n­avirus vac­ci­na­tion either elec­tron­i­cal­ly or by phone:

  • electronic appointment booking in the Omahoito service on the address: https://soite.terveytesi.fi, the service opens on Friday 26th of February 2021 at 12 noon. You have to log in to the Omahoito service with your own bank codes (or other secure identification) before you can book an appointment for yourself. 
  • appointment booking opens on Tuesday March 2nd at 12 o’clock at the number 06 828 7488. The phone booking will be open as long as there are appointments available. At other times, you will hear a recorded message.

The elec­tron­ic appoint­ment book­ing runs more smooth­ly and we rec­om­mend that you book your appoint­ment online if possible.

Per­sons under the age of 18 (i.e. 16–18-year-olds) who belong to risk group 1 are vac­ci­nat­ed at the Chil­dren’s hos­pi­tal (Lastensairaala/Barnsjukhuset).

Per­sons younger than 70 will be vac­ci­nat­ed using AstraZeneca’s vac­cine. Per­sons who live in the same house­hold as an at-risk per­son are not eli­gi­ble for vac­ci­na­tion at this stage.

Be pre­pared to prove that you belong to a risk group

When you arrive at the vac­ci­na­tion site, be pre­pared to prove that you belong to a risk group (e.g. by show­ing your Kela card or a copy of your epi­cri­sis or pre­scrip­tion). Group 1 con­sists of 16–69 year-olds with an ill­ness or con­di­tion that is high­ly pre­dis­pos­ing to severe coro­n­avirus disease:

  • Organ transplant or stem cell transplant

This group includes peo­ple who have received an organ trans­plant and peo­ple who have received a stem cell trans­plant no more than six months ago. The group also includes every­one who uses anti-rejec­tion med­ica­tion due to stem cell trans­plan­ta­tion, regard­less of the time of the stem cell transplantation.

Anti-rejec­tion med­ica­tion sup­press­es the immune sys­tem. Accord­ing to inter­na­tion­al lit­er­a­ture, use of anti-rejec­tion med­ica­tion mul­ti­plies the risk of severe COVID-19 disease.

  • People undergoing active cancer treatment

The group includes those with a can­cer that strong­ly impairs the func­tion of the immune sys­tem. These include some types of leukaemia and lym­phoma.  The group also includes those whose can­cer is treat­ed in a way that strong­ly weak­ens their immune defence.

In addi­tion, the group includes per­sons receiv­ing a type of can­cer ther­a­py that impairs immune defence to reduce symp­toms or to slow the can­cer down. The group also includes those who have been get­ting a type of drug treat­ment that sig­nif­i­cant­ly weak­ens immune defence no more than 6 months earlier.

The group does not include per­sons whose can­cer has been treat­ed only sur­gi­cal­ly or who receive treat­ment that does not affect the immune defence. Such treat­ment includes adju­vant hor­mon­al ther­a­py for breast cancer.

Espe­cial­ly haema­to­log­i­cal can­cers or blood can­cers, such as leukaemias and lym­phomas, increase the risk of severe dis­ease because the can­cer tar­gets cells in the human body that pro­tect against infec­tion. In addi­tion, can­cer treat­ments often include med­ica­tion that weak­ens the immune defence system.

  • Severe disorders of the immune system 

This group includes peo­ple with severe inher­it­ed immun­od­e­fi­cien­cy or low­ered resis­tance due to anoth­er rea­son.   In addi­tion, the group includes HIV-pos­i­tive per­sons with a CD4 helper cell lev­el of less than 0.350 x 109 cells/l and per­sons who have had their spleen removed. The group also includes e.g. per­sons whose rare dis­eases affect immune defence.

In this risk group, the con­di­tion itself caus­es an abnor­mal immune response. The group does not include mild abnor­mal­i­ties com­mon in gen­er­al pop­u­la­tion, such as IgA defi­cien­cy, defi­cien­cy of man­nose-bind­ing lectin or par­tial defi­cien­cy of com­ple­ment fac­tor C4.

  • Severe chronic renal disease

This group includes, for exam­ple, peo­ple with renal dis­ease requir­ing dial­y­sis, glomeru­lar dis­ease, renal dam­age relat­ed to hyper­ten­sion or dia­betes, or oth­er chron­ic renal failure.

Severe renal fail­ure is known to pre­dis­pose to severe infec­tions. On the oth­er hand, COVID-19 infec­tion can com­pli­cate chron­ic renal dis­eases. On the oth­er hand, COVID-19 infec­tion can com­pli­cate chron­ic renal diseases.

In stud­ies of the risk of hos­pi­tal­i­sa­tion, admis­sion to an inten­sive care unit or death, renal fail­ure was almost with­out excep­tion more com­mon among patients with the most severe form of COVID-19.

  • Severe chronic pulmonary disease 

This group includes, for exam­ple, chron­ic obstruc­tive pul­monary dis­ease (COPD), pul­monary emphy­se­ma, bronchial dilata­tion, chron­ic bron­chi­tis and cys­tic fibrosis.

The group also includes peo­ple with clear­ly decreased lung capac­i­ty (e.g. peo­ple with one lung) and peo­ple with asth­ma who have tak­en cor­ti­cos­teroid tablets by mouth dur­ing the past year.

Peo­ple suf­fer­ing from dif­fi­cult-to-man­age asth­ma are vac­ci­nat­ed in group 1 (Peo­ple with an ill­ness or con­di­tion that is high­ly pre­dis­pos­ing to severe coro­n­avirus dis­ease) and oth­er peo­ple suf­fer­ing from asth­ma in group 2 (Peo­ple with an ill­ness or con­di­tion that is pre­dis­pos­ing to severe coro­n­avirus disease).

Chron­ic pul­monary dis­eases impair breath­ing capac­i­ty and can com­pli­cate the coro­n­avirus dis­ease. Also, COVID-19 infec­tion can, in turn, fur­ther com­pli­cate the chron­ic pul­monary disease.

Use of cor­ti­sone tablets tak­en by mouth can be con­sid­ered a sign of poor­ly con­trolled asthma.

  • Type 2 diabetes with medication 

This group includes type 2 dia­betes requir­ing med­ica­tion. High blood glu­cose is known to increase sus­cep­ti­bil­i­ty to infec­tion. In addi­tion, acute infec­tions impair the treat­ment of dia­betes.  Type 2 dia­betes is often asso­ci­at­ed with obe­si­ty, which in turn also increas­es the risk of severe coro­n­avirus disease.

  • Down syndrome

This group includes peo­ple above 16 years of age with Down syndrome.

Down syn­drome is asso­ci­at­ed with abnor­mal­i­ties of the immune sys­tem that man­i­fest, for exam­ple, as sus­cep­ti­bil­i­ty to infec­tion. Also, COVID-19 infec­tion can com­pli­cate prob­lems caused by struc­tur­al anom­alies asso­ci­at­ed with the syn­drome (e.g. con­gen­i­tal heart dis­ease).  Addi­tion­al infor­ma­tion at THL’s web site.

koronavilkku-banneri-mobiili

Social Media